Evidence map›Paper›PMID 39128634›Full record

ArticleUrology2024

Long-term Outcomes of Regressed or "Burnt Out" Primary Testicular Germ Cell Tumors.

Fady J Baky, Nicole Liso, Brandon Williams, Victor E Reuter, Satish K Tickoo, Darren R Feldman, Samuel A Funt, Brett S Carver, Joel Sheinfeld, Richard S Matulewicz

Abstract read
In one paragraph

Article in Urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Fady J BakyMemorial Sloan Kettering Cancer Center, Urology Service, Department of Surgery, New York, NY.
Nicole LisoMemorial Sloan Kettering Cancer Center, Urology Service, Department of Surgery, New York, NY.
Brandon WilliamsMemorial Sloan Kettering Cancer Center, Urology Service, Department of Surgery, New York, NY.
Victor E ReuterMemorial Sloan Kettering Cancer Center, Department of Pathology & Laboratory Medicine, New York, NY; Weill Cornell Medical College, Department of Pathology and Laboratory Medicine, New York, NY.
Satish K TickooMemorial Sloan Kettering Cancer Center, Department of Pathology & Laboratory Medicine, New York, NY.
Darren R FeldmanMemorial Sloan Kettering Cancer Center, Genitourinary Oncology Service, Department of Medicine, New York, NY; Weill Cornell Medical College, Department of Medicine, New York, NY.
Samuel A FuntMemorial Sloan Kettering Cancer Center, Genitourinary Oncology Service, Department of Medicine, New York, NY; Weill Cornell Medical College, Department of Medicine, New York, NY.
Brett S CarverMemorial Sloan Kettering Cancer Center, Urology Service, Department of Surgery, New York, NY; Weill Cornell Medical College, Department of Urology, New York, NY.
Joel SheinfeldMemorial Sloan Kettering Cancer Center, Urology Service, Department of Surgery, New York, NY; Weill Cornell Medical College, Department of Urology, New York, NY.
Richard S MatulewiczMemorial Sloan Kettering Cancer Center, Urology Service, Department of Surgery, New York, NY; Weill Cornell Medical College, Department of Urology, New York, NY. Electronic address: matulewr@mskcc.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

objectiveTo review the presentation and long-term oncologic outcomes of patients with regressed ("burnt out") primary testicular germ cell tumors (GCT). Certain testicular GCT can present with complete regression of the primary tumor. It is not well established if this is associated with more aggressive disease or worse oncologic outcomes.

methodsWe queried our prospectively maintained testicular cancer clinical database at a tertiary cancer center and identified patients without prior chemotherapy who had regressed primary GCT at radical orchiectomy from 1990 to 2023. All specimens were reviewed by a genitourinary pathologist at diagnosis. Long-term clinical outcomes were reported by Kaplan-Meier method.

resultsFifty-six patients met inclusion criteria; at diagnosis, 17 had no evidence of extra-testicular disease and 39 had advanced (clinical stage [CS] II+) GCT. All CSx (no viable disease or germ cell neoplasia in situ at orchiectomy, and no evidence of advanced disease) and CS0 patients were managed with surveillance and had 5-year recurrence-free survival (RFS) of 88% (95% CI: 39%, 98%). All patients with CS II+ disease underwent primary treatment with surgery (n = 5) or first-line chemotherapy (n = 34). Two- and 5-year RFS for patients with CSII+ disease was 94% (95% CI: 78%, 98%) and 90% (95% CI: 72%, 97%), respectively.

conclusionPatients with regressed primary testicular GCT often present with advanced disease, possibly due to lack of early clinical signs from the primary tumor. Our analysis shows excellent long-term oncologic outcomes similar to those reported in the literature for patients with viable primary testicular GCT.

Indexed as

Neoplasms, Germ Cell and EmbryonalOrchiectomyTesticular NeoplasmsAdultHumansMaleMiddle AgedNeoplasm StagingRetrospective StudiesTime FactorsTreatment OutcomeYoung Adult

Identifiers

PMID39128634
PMCPMC11560521

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.